• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603567.SS
Share

Heilongjiang ZBD Pharmaceutical Co., Ltd. Stocks

CN¥ 4.76Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 663.71M

CN¥ 4.76
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Heilongjiang ZBD Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the entire lifecycle of Traditional Chinese Medicine (TCM), from research and development to manufacturing and sales, exclusively within China. Its extensive product portfolio addresses a wide spectrum of health concerns, including conditions related to cardiovascular and cerebrovascular health, respiratory ailments, orthopedic issues, oncology, digestive disorders, anti-infective treatments, neuropsychiatric conditions, and genitourinary problems, among others. Established in 1996, the company maintains its headquarters in Hulin, China.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, undervalued on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 18:44

Kaspi.kz has completed the acquisition of Turkey's Rabobank

15.07.2026 18:25

Shares of a mid-cap company that develops chip-testing solutions have skyrocketed. Why?

15.07.2026 18:04

Wholesale prices in the U.S. fell in June—a development the market did not expect

15.07.2026 17:30

Assets under management at BlackRock exceeded $15 trillion for the first time

15.07.2026 17:00

OpenAI's first device will be a "smart speaker." Will this create competition for Apple?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026